Basic Information
Bio4t2 is a global, clinical-stage private biopharmaceutical company that produces CAR-T cells using proprietary technology to recognize autologous antigens overexpressed on solid tumors. The company's proprietary PrismCore™ platform combines algorithmic learning with supervised and iterative design of CARs to rapidly generate genetically modified T cells for optimal functional outcomes. Operating in both China and the United States, Bio4t2 can quickly advance CAR-T therapies into clinical trials to explore their therapeutic potential. Bio4t2 is one of the portfolio companies of Bridgewest Group.